Xconomy.com -- Ironwood Pharmaceuticals, a Cambridge, MA-based firm with a lead product candidate for chronic constipation, said in an SEC filing that it has set the price of its proposed initial public offering at $14 to $16 per share. The firm is aiming to sell 16.7 million shares of common stock in the IPO, which would make the stock sale worth up to $266.7 million—a good deal more than the initial $172.5 million estimate that the firm gave when it first disclosed plans for the maiden stock offering in November 2009.
